DrugNews Adds New Study Data and Legal News for Pradaxa

http://www.DrugNews.net is the web’s premier source for prescription device warnings, research, side effects and legal news. Visit the DrugNews Center today.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Many patients have already filed a Pradaxa lawsuit alleging internal bleeding, resulting in cases being consolidated to a special federal multidistrict litigation court.

New York, NY (PRWEB) January 28, 2014

The prescription drug safety advocates at DrugNews.net have added new information to the site for patients taking the blood thinner Pradaxa. The resource center learned the FDA is planning a new study of the drug’s safety* and court records show the number of lawsuits alleging internal bleeding from Pradaxa have risen for January**.

DrugNews was created to improve patient safety by sharing the latest safety alerts, research, litigation news and recalls with those taking popular prescription drugs. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.

Pradaxa is a blood thinner approved by the FDA in 2010 to prevent blood clots and strokes in patients with atrial fibrillation. The resource center has compiled conflicting reports from experts, however, about whether it increases risks of internal bleeding.

The FDA previously claimed Pradaxa was as safe as traditional blood thinner warfarin***. The Institute for Safe Medication Practices though warned that Pradaxa bleeding may be almost 5 times as likely to cause death****. A recent study also suggested patients taking blood thinners like Pradaxa may be 55% more likely to suffer internal bleeding*****.

DrugNews has now learned the FDA plans a new study to measure the rates of Pradaxa bleeding and blood clots compared with warfarin among patients with atrial fibrillation*.

Many patients have already filed a Pradaxa lawsuit alleging internal bleeding, resulting in cases being consolidated to a special federal multidistrict litigation court. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

The latest court data added by the resource center shows the number of cases filed rose from 1,936 on December 16th to 2,057 on January 15th**, an increase of over 6%.

Anyone affected by internal bleeding after taking Pradaxa is encouraged to visit DrugNews.net or speak with a lawyer about their legal options. Due to the specialized nature of these cases, DrugNews only recommends lawyers who have already handled Pradaxa lawsuits.

Visit http://www.DrugNews.net today for more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer.

*Forbes, 1/3/14; forbes.com/sites/larryhusten/2014/01/03/fda-plans-new-safety-assessment-of-dabigatran-pradaxa/
**Judicial Panel on Multidistrict Litigation, 1/15/14; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-January-15-2014.pdf
***FDA, 11/2/12; http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
****Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
*****Gastroenterology, July 2013; gastrojournal.org/article/S0016-5085(13)00290-4/fulltext


Contact